Coronavirus Spike Glycoprotein (CoV S) peptide (Cy5)
CoV S
Reaktivität: Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
Wirt: Synthetic
InhA
3 Abbildungen
(3 Referenzen)Kurzübersicht für Coronavirus Spike Glycoprotein (CoV S) peptide (Cy5) (ABIN6952489)
Target
Coronavirus Spike Glycoprotein (CoV S)
Spezies
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
Quelle
Synthetic
Applikation
Inhibition Assay (InhA)
-
-
Aufreinigungstag / Konjugat
- Dieses Coronavirus Spike Glycoprotein Peptid ist gelabelt mit Cy5.
-
Sequenz
- Cy5-SLDQINVTFL DLEYEMKKLE EAIKKLEESY IDLKEL
-
Produktmerkmale
- EK1 / Pan-HCoV S Inhibitor - Cy5 Labeled
-
Reinheit
- ≥ 90 %
-
Bestandteile
- Each vial contains 1 nmol of NET labeled peptide.
-
-
Coronavirus Spike Glycoprotein (CoV S) peptide
CoV S Reaktivität: Middle East Respiratory Syndrome Coronavirus (MERS-CoV), SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2) Wirt: Synthetic InhA
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Powder
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Store in dry form in a dark place with temperature 0-5°C.
-
-
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
: "Drug treatment options for the 2019-new coronavirus (2019-nCoV)." in: Bioscience trends, Vol. 14, Issue 1, pp. 69-71, (2020) (PubMed).
: "A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike." in: Science advances, Vol. 5, Issue 4, pp. eaav4580, (2019) (PubMed).
-
: "Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein." in: Cellular & molecular immunology, (2020) (PubMed).
-
- Coronavirus Spike Glycoprotein (CoV S)
-
Substanzklasse
- Viral Protein
-
Molekulargewicht
- 4332
Target
-
Sie sind hier:
